| Product dosage: 150mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.37 | $41.14 (0%) | 🛒 Add to cart |
| 60 | $1.07 | $82.28 $64.22 (22%) | 🛒 Add to cart |
| 90 | $0.97 | $123.42 $87.30 (29%) | 🛒 Add to cart |
| 120 | $0.93 | $164.56 $111.38 (32%) | 🛒 Add to cart |
| 180 | $0.88 | $246.84 $157.54 (36%) | 🛒 Add to cart |
| 270 | $0.84 | $370.26 $227.77 (38%) | 🛒 Add to cart |
| 360 | $0.83
Best per pill | $493.68 $298.01 (40%) | 🛒 Add to cart |
Similar products
More info:
Bupropion: Effective Depression and Smoking Cessation Treatment - Evidence-Based Review
Bupropion is an atypical antidepressant and smoking cessation aid belonging to the norepinephrine-dopamine reuptake inhibitor (NDRI) class. Unlike traditional SSRIs, it uniquely increases dopamine and norepinephrine activity without significant serotonergic effects, which explains its distinct therapeutic profile and side effect pattern. Initially approved in 1985 and available under brand names like Wellbutrin and Zyban, it has become a cornerstone in managing major depressive disorder, seasonal affective disorder, and nicotine dependence, particularly valued for its minimal sexual side effects and potential for weight neutrality or loss.
armod
The product in question is a wakefulness-promoting agent containing armodafinil as the active pharmaceutical ingredient. Armodafinil represents the R-enantiomer of modafinil, developed to provide more consistent plasma concentrations throughout the waking day compared to the racemic mixture. In clinical practice, we’ve observed it functions as a eugeroic or “good arousal” agent with a different neurochemical profile than traditional stimulants, acting through multiple neurotransmitter systems including dopamine, norepinephrine, orexin, and histamine pathways.
Asendin: A Potent Antidepressant for Treatment-Resistant Depression - Evidence-Based Review
Before we get to the formal headings, let me give you the real picture of Asendin. It’s not just another entry in the crowded antidepressant market; it’s a tricyclic antidepressant (TCA), specifically amoxapine, that occupies this fascinating, somewhat contentious niche. We initially viewed it as a fallback option when SSRIs failed, but over the years, I’ve seen its unique profile—part TCA, part subtle dopamine modulator—make a tangible difference for a specific subset of patients who feel nothing from the first-line drugs.
bupron sr
Bupron SR represents one of those interesting cases where the sustained-release mechanism actually makes clinical sense, unlike so many other SR formulations where it’s mostly a marketing gimmick. We initially approached this with skepticism - another sustained-release antidepressant? But the pharmacokinetic profile turned out to be genuinely useful, particularly for patients who struggled with the peak-trough fluctuations of immediate-release bupropion. ## 1. Introduction: What is Bupron SR? Its Role in Modern Medicine
champix
Let me tell you about Champix - it’s one of those products that completely changed how we approach smoking cessation in clinical practice. When Pfizer first introduced varenicline (that’s the active pharmaceutical ingredient in Champix), we were all pretty skeptical in our pulmonary medicine department. Another smoking cessation aid? Really? We already had nicotine replacement therapies and bupropion, which worked okay for some patients but had significant limitations. Champix tablets contain varenicline tartrate, which acts as a partial agonist specifically targeting the α4β2 nicotinic acetylcholine receptors.
contrave
Contrave represents one of the more interesting pharmacological approaches to weight management we’ve seen in recent years—it’s not just another appetite suppressant but rather a combination product that works on both the hunger and reward pathways in the brain. When I first reviewed the clinical trial data back in 2014, I was skeptical about combining bupropion and naltrexone, given their individual profiles, but the synergy is what makes it compelling for appropriate patients.
emsam
Emsam represents one of the more elegant solutions in modern psychopharmacology – a transdermal monoamine oxidase inhibitor (MAOI) delivering selegiline through a patch delivery system. When we first started working with this formulation back in the early clinical trials, I remember our team being divided between those who saw it as just another antidepressant and those who recognized its unique potential for treatment-resistant cases. The patch system itself was actually adapted from nicotine cessation technology, which created some interesting formulation challenges our pharmacologists argued about for months.
fluoxetine
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) antidepressant that has fundamentally changed how we approach mood and anxiety disorders. When I first started in psychiatry back in the late 90s, the tricyclics were still dominant, but the side effect profiles were brutal. Then fluoxetine came along—Prozac was the brand name everyone knew—and it felt like we finally had something that patients could actually tolerate long-term. It wasn’t a miracle cure, nothing is, but it gave us a real fighting chance against major depressive disorder.
Geodon: Effective Symptom Control for Schizophrenia and Bipolar Disorder - Evidence-Based Review
Geodon, known generically as ziprasidone, is an atypical antipsychotic medication approved for the treatment of schizophrenia and acute manic or mixed episodes associated with bipolar disorder. It belongs to the benzisoxazole class and functions primarily as a dopamine and serotonin antagonist, with a unique receptor binding profile that distinguishes it from earlier antipsychotics. Available in both oral capsule and intramuscular injection forms, Geodon offers clinicians a versatile option for managing acute agitation and long-term psychotic symptoms.